1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione hydrochloride

• ChemBase ID: 179717
• Molecular Formular: C22H29ClN4O6
• Molecular Mass: 480.94186
• Monoisotopic Mass: 480.17756235
• SMILES: c12c(C(=O)c3c(C1=O)c(ccc3O)O)c(ccc2NCCNCCO)NCCNCCO.Cl
• Canonical SMILES: OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO.Cl
• InChI: InChI=1S/C22H28N4O6.ClH/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;/h1-4,23-30H,5-12H2;1H
• InChIKey: MKCBCZDNNZPMCG-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione hydrochloride
• IUPAC Traditional name: 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione hydrochloride
• Synonyms: Metrisone; Misostrol; Novantron; Novantrone; Novatrone; Refador; Mitoxantrone Hydrochloride

Database IDs

• CAS Number: 70476-82-3
• PubChem SID: 164235627
• PubChem CID: 5458171

CALCULATED PROPERTIES

• Acid pKa: 9.775683
• H Acceptors: 10
• H Donor: 8
• LogD (pH = 5.5): -4.25051
• LogD (pH = 7.4): -1.2001225
• Log P: 1.1855145
• Molar Refractivity: 123.5338 cm^3
• Polarizability: 45.86351 Å^3
• Polar Surface Area: 163.18 Å^2
• Rotatable Bonds: 12
• Lipinski's Rule of Five: false

PROPERTIES

Pharmacology Properties

• Mechanism of Action: DNA intercalator

Product Information

• Salt Data: HCl
• Application(s): Antineoplastic agent against; metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma

REFERENCES

• Zee-Cheng, R.K.Y. et al., J. Med. Chem., 1978, 21, 291; 1979, 22, 501, (synth, uv, pharmacol)
• Murdock, K.C. et al., J. Med. Chem., 1979, 22, 1024, (synth, pharmacol)
• Taylor, R.F. et al., J. Chromatogr., 1980, 187, 212, (hplc)
• Henderson, B.M. et al., Cancer Treat. Rep., 1982, 66, 1139, (tox)
• Beijnen, J.H. et al., Anal. Profiles Drug Subst., 1988, 17, 221, (rev)
• Koeller, J. et al., Clin. Pharm., 1988, 7, 574, (rev, pharmacol)
• Ehninger, G. et al., Clin. Pharmacokinet., 1990, 18, 365, (rev, pharmacokinet)
• Faulds, D. et al., Drugs, 1991, 41, 400, (rev)
• Textbook of Adverse Drug Reactions, 4th edn., (ed. Davies, D.M.), Oxford University Press, 1991, (tox)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 494
• Catalin, J. et al., Biomed. Chromatogr., 1994, 8, 37, (hplc)
• Panousis, C. et al., Nucleic Acids Res., 1994, 22, 1342, (pharmacol)
• Venitt, S. et al., J. Med. Chem., 1998, 41, 3748-3752, (pharmacol)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, MQY090; MQY100